肿瘤细胞治疗研究
英文原题：Anti-BCMA and GPRC5D bispecific antibodies in relapsed/refractory primary plasma cell leukemia: a case report.
Anti-BCMA and GPRC5D bispecific antibodies in relapsed/refractory primary plasma cell leukemia: a case report.
浆细胞白血病（PCL）是多发性骨髓瘤（MM）的一种侵袭性高危变异型，预后极差。
浆细胞白血病（PCL）是多发性骨髓瘤（MM）一种侵袭性强的高危亚型，预后极差。由于该病罕见且侵袭性高，缺乏评估新疗法疗效的临床试验。包括靶向B细胞成熟抗原（BCMA）和G蛋白偶联受体C类5组D型（GPRC5D）的新型免疫治疗药物，特别是嵌合抗原受体（CAR）T细胞和双特异性抗体，可能在PCL治疗中发挥作用。然而，近期评估这些药物的关键临床试验排除了PCL患者，目前仅有少数病例报告。本文介绍本中心一名复发/难治性原发性PCL患者接受抗BCMA和抗GPRC5D双特异性抗体治疗的临床经过。
Plasma cell leukemia (PCL) is an aggressive and high-risk variant of multiple myeloma (MM) with a very poor prognosis. Given its rarity and aggressiveness, there is a lack of clinical trials testing the efficacity of novel therapies in these patients. New immune approaches such as B-cell maturation antigen (BCMA) and G protein-coupled receptor, family C, group 5, member D (GPRC5D) -targeting agents, including chimeric antigen receptor (CAR) T-cells and bispecific antibodies could play a role in PCL treatment. However, PCL patients were excluded from recent pivotal clinical trials testing those agents and only some case reports have been published. We present here the clinical course of a patient with relapsed/refractory (R/R) primary (p) PCL who was treated with anti-BCMA and anti-GPRC5D bispecific antibodies at our center.
MEMBER ACCOUNT
登录成功会直接打开下一页。
